{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:27Z","timestamp":1791262347712,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110525","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:43:13Z","timestamp":1789515793000},"page":"110525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Thieno[2,3-d]pyrimidine scaffold optimization for synergistic c-Met\/STAT3 blockade: Synthesis, structure-activity relationships, in vitro potency, and apoptotic pathways in colorectal cancer"],"prefix":"10.1016","volume":"182","author":[{"given":"Shaimaa I.","family":"El-Desouky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Haffez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Nafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ahmed A.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.21037\/jtd.2017.02.75","article-title":"Cancer prevention from the perspective of global cancer burden patterns","volume":"9","author":"Nagai","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110525_bb0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.46747\/cfp.6807515","article-title":"Targeted cancer therapies: clinical pearls for primary care","volume":"68","author":"Shuel","year":"2022","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.bioorg.2026.110525_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.910268","article-title":"The hepatocyte growth factor\/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents","volume":"10","author":"Grundy","year":"2022","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3892\/ijo.2012.1728","article-title":"HGF regulates VEGF expression via the c-met receptor downstream pathways, PI3K\/Akt, MAPK and STAT3, in CT26 murine cells","volume":"42","author":"Matsumura","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110525_bb0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ab.2011.01.028","article-title":"Molecular imaging of c-met tyrosine kinase activity","volume":"412","author":"Zhang","year":"2011","journal-title":"Anal. Biochem."},{"issue":"03","key":"10.1016\/j.bioorg.2026.110525_bb0040","first-page":"148","article-title":"Targeting MET in cancer therapy","volume":"3","author":"Mo","year":"2017","journal-title":"Chronic Dis. Transl. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biology12020287","article-title":"CAR based immunotherapy of solid tumours\u2014a clinically based review of target antigens","volume":"12","author":"Maher","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.bioorg.2026.110525_bb0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jmgm.2017.04.004","article-title":"Development of efficient docking strategies and structure-activity relationship study of the c-met type II inhibitors","volume":"75","author":"Li","year":"2017","journal-title":"J. Mol. Graph. Model."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0055","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s11030-021-10267-7","article-title":"Type II c-met inhibitors: molecular insight into crucial interactions for effective inhibition","volume":"26","author":"Damghani","year":"2022","journal-title":"Mol. Divers."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110525_bb0060","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.bmc.2013.04.013","article-title":"Discovery of novel 4-(2-fluorophenoxy) quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-met kinase inhibitors","volume":"21","author":"Li","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110525_bb0065","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.bmc.2013.06.026","article-title":"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-met kinase inhibitors","volume":"21","author":"Qi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1871520611009010007","article-title":"Discovery of small molecule c-met inhibitors: evolution and profiles of clinical candidates","volume":"10","author":"Underiner","year":"2010","journal-title":"Anticancer Agents Med Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110525_bb0075","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-10-2527","article-title":"VEGF and c-met blockade amplify angiogenesis inhibition in pancreatic islet cancer","volume":"71","author":"You","year":"2011","journal-title":"Cancer Res. J."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110525_bb0080","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110525_bb0085","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res. J."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0090","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.29496","article-title":"Recent developments of c-met as a therapeutic target in hepatocellular carcinoma","volume":"67","author":"Bouattour","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110525_bb0095","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the met kinase superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1158\/0008-5472.CAN-13-1103","article-title":"MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation","volume":"74","author":"Rho","year":"2014","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110525_bb0105","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/sj.onc.1203476","article-title":"The role of STATs in transcriptional control and their impact on cellular function","volume":"19","author":"Bromberg","year":"2000","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110525_bb0110","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.124","article-title":"STAT3 pathway in cancers: past, present, and future","volume":"3","author":"Wang","year":"2022","journal-title":"MedComm"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/ijms22020603","article-title":"The multifaced role of STAT3 in cancer and its implication for anticancer therapy","volume":"22","author":"Tolomeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110525_bb0125","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer\u2014new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110525_bb0135","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrc906","article-title":"Transcription factors as targets for cancer therapy","volume":"2","author":"Darnell","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110525_bb0145","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/biomedicines9081016","article-title":"Targeting STAT3 signaling pathway in colorectal cancer","volume":"9","author":"Gargalionis","year":"2021","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110525_bb0150","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.3390\/cancers12092459","article-title":"STAT3, the challenge for chemotherapeutic and radiotherapeutic efficacy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110525_bb0155","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2174\/0929867329666220819093117","article-title":"Discovery of STAT3 inhibitors: recent advances and future perspectives","volume":"30","author":"Song","year":"2023","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054565","article-title":"Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo-and radio-sensitivity in nasopharyngeal carcinoma","volume":"8","author":"Pan","year":"2013","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110525_bb0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2468-1253(18)30009-8","article-title":"Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial","volume":"3","author":"Jonker","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.110525_bb0170","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejmech.2014.05.049","article-title":"Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)","volume":"82","author":"Chen","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0175","doi-asserted-by":"crossref","unstructured":"J.d. Groot, M. Ott, J. Wei, C. Kassab, D. Fang, H. Najem, B. O'Brien, S.-P. Weathers, C.K. Matsouka, N.K. Majd, A first-in-human phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma, CNS Oncol. 11(2) (2022) CNS87.","DOI":"10.2217\/cns-2022-0005"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0180","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.110525_bb0185","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: the next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"1 Suppl","key":"10.1016\/j.bioorg.2026.110525_bb0190","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1749-6632.2009.04911.x","article-title":"Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?","volume":"1171","author":"Aggarwal","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.exer.2005.01.016","article-title":"STAT3 activation in response to growth factors or cytokines participates in retina precursor proliferation","volume":"81","author":"Zhang","year":"2005","journal-title":"Exp. Eye Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110525_bb0205","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/mc.23306","article-title":"Feed-forward activation of STAT3 signaling limits the efficacy of c-met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment","volume":"60","author":"Zhao","year":"2021","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2026.110525_bb0210","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.canlet.2021.07.048","article-title":"STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells","volume":"519","author":"Zhu","year":"2021","journal-title":"Cancer Lett."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110525_bb0215","doi-asserted-by":"crossref","first-page":"14472","DOI":"10.18632\/oncotarget.3991","article-title":"Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110525_bb0220","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejmech.2015.08.018","article-title":"Recent developments regarding the use of thieno[2,3-d]pyrimidin-4-one derivatives in medicinal chemistry, with a focus on their synthesis and anticancer properties","volume":"102","author":"Bozorov","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejmech.2012.07.007","article-title":"Design, synthesis and biological evaluation of some novel thienopyrimidines and fused thienopyrimidines as anti-inflammatory agents","volume":"55","author":"Rizk","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0230","first-page":"439","article-title":"Synthesis and antimicrobial activity of new substituted thienopyrimidines, their tetrazolyl and sugar derivatives","volume":"69","author":"El-Sayed","year":"2012","journal-title":"Acta Pol. Pharm."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110525_bb0235","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.bmc.2019.02.044","article-title":"Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: recent advances","volume":"27","author":"Ali","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110525_bb0240","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1016\/j.bmc.2017.11.010","article-title":"Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-met and VEGFR-2 kinase inhibitors","volume":"25","author":"Li","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110525_bb0245","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1016\/j.bmc.2011.05.038","article-title":"Discovery of novel c-met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold","volume":"19","author":"Zhao","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0250","series-title":"Probe Reports from the NIH Molecular Libraries Program [Internet]","article-title":"Modulators of STAT transcription factors for the targeted therapy of cancer (STAT3 Inhibitors)","author":"Madoux","year":"2009"},{"key":"10.1016\/j.bioorg.2026.110525_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107101","article-title":"Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities","volume":"143","author":"Elsebaie","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108821","article-title":"Scaffold-hopping strategy for pyrazolo[3,4-d]pyrimidines: in vitro and in silico studies of dual c-met\/STAT3 inhibition for enhanced antitumor activity","volume":"164","author":"El-Desouky","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"2\u20133","key":"10.1016\/j.bioorg.2026.110525_bb0265","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0163-7258(98)00044-8","article-title":"Strategies toward the design of novel and selective protein tyrosine kinase inhibitors","volume":"82","author":"Traxler","year":"1999","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/jm020241c","volume":"46","author":"Wissner","year":"2003","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110525_bb0275","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.bmcl.2017.02.032","article-title":"Synthesis and antibacterial activity of 3-benzylamide derivatives as FtsZ inhibitors","volume":"27","author":"Hu","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110525_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112257","article-title":"Design, synthesis and biological evaluation of novel naturally-inspired multifunctional molecules for the management of Alzheimer\u2019s disease","volume":"198","author":"Singh","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0285","series-title":"3,6-Disubstituted-2-Pyridinaldoxime Scaffolds","author":"Baati","year":"2020"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0290","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1134\/S001250081908007X","article-title":"Novel ferrocene-containing thiophene derivatives","volume":"487","author":"Rodlovskaya","year":"2019","journal-title":"Dokl. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0295","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jhet.5570450333","article-title":"Synthesis of substituted amino-cycloalkyl[b]thieno[3,2-e]pyridines","volume":"45","author":"Seck","year":"2008","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103890","article-title":"Synthesis, in vivo anti-inflammatory, COX-1\/COX-2 and 5-LOX inhibitory activities of new 2,3,4-trisubstituted thiophene derivatives","volume":"102","author":"Qandeel","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0305","series-title":"HPK1 Inhibitor and Application Thereof","author":"Wu","year":"2019"},{"key":"10.1016\/j.bioorg.2026.110525_bb0310","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejmech.2014.08.056","article-title":"Synthesis and evaluation of 4-anilinoquinazoline bioisosteres as potential anti-breast cancer agents","volume":"86","author":"El-Ansary","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0315","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejmech.2019.01.061","article-title":"Subtle modifications to a thieno[2,3-d] pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D2 receptor","volume":"168","author":"Fyfe","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110525_bb0320","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1080\/00397919608003791","article-title":"Synthesis and application of some new thienopyrimidine derivatives as antimicrobial agents","volume":"26","author":"Hozien","year":"1996","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2026.110525_bb0325","doi-asserted-by":"crossref","unstructured":"A. Faiella, F. Riccardi, G. Carten\u00ec, M. Chiurazzi, L. Onofrio, The emerging role of c-met in carcinogenesis and clinical implications as a possible therapeutic target, J. Oncol. 2022(1) (2022) 5179182.","DOI":"10.1155\/2022\/5179182"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0330","first-page":"165","article-title":"C-MET overexpression in colorectal cancer: a poor prognostic factor for survival","volume":"17","author":"Lee","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110525_bb0335","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/13543784.2011.631523","article-title":"The role of HGF\/c-met signaling in prostate cancer progression and c-met inhibitors in clinical trials","volume":"20","author":"Varkaris","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.110525_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107682","article-title":"Fragment-based design and synthesis of coumarin-based thiazoles as dual c-MET\/STAT-3 inhibitors for potential antitumor agents","volume":"151","author":"Naguib","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113333","article-title":"Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors","volume":"216","author":"Gao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"26","key":"10.1016\/j.bioorg.2026.110525_bb0350","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood-2015-07-658823","article-title":"Targeting HGF\/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma","volume":"126","author":"Dai","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110525_bb0355","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-021-04242-0","article-title":"Foretinib induces G2\/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition","volume":"87","author":"Gortany","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0360","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13046-015-0238-2","article-title":"Tivantinib induces G2\/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma","volume":"34","author":"Xiang","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110525_bb0365","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/abbs\/gmy174","article-title":"E2F is required for STAT3-mediated upregulation of cyclin B1 and Cdc2 expressions and contributes to G2-M phase transition","volume":"51","author":"Sun","year":"2019","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110525_bb0370","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/ijc.30847","article-title":"Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma","volume":"141","author":"Bixel","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0375","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","article-title":"Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: implications for counteracting tumor immune evasion","volume":"23","author":"Xia","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.110525_bb0380","series-title":"Cancer Cell Metabolism: A Potential Target for cancer Therapy","first-page":"89","article-title":"Role of c-Met\/HGF axis in altered cancer metabolism","author":"Chandel","year":"2020"},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2026.110525_bb0385","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0005-2728(98)00108-X","article-title":"Bcl-2 family proteins and mitochondria","volume":"1366","author":"Reed","year":"1998","journal-title":"Biochim. Biophys. Acta-Bioenerg."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3260001","article-title":"Caspases: the executioners of apoptosis","volume":"326","author":"Cohen","year":"1997","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110525_bb0395","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"56","key":"10.1016\/j.bioorg.2026.110525_bb0400","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.bioorg.2026.110525_bb0405","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1128\/MCB.25.17.7432-7440.2005","article-title":"Role of Stat3 in regulating p53 expression and function","volume":"25","author":"Niu","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2026.110525_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106988","article-title":"Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-met and Pim-1 inhibitors: design, synthesis, SAR and in silico study","volume":"143","author":"Mohamady","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110525_bb0415","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.bioorg.2026.110525_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-0509-8-S4-S11","article-title":"CytoHubba: identifying hub objects and sub-networks from complex interactome","volume":"8","author":"Chin","year":"2014","journal-title":"BMC Syst. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0425","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1038\/s41598-018-23395-2","article-title":"Interpretation of biological experiments changes with evolution of the gene ontology and its annotations","volume":"8","author":"Tomczak","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110525_bb0430","series-title":"Bioinformatics in Aquaculture: Principles and Methods","first-page":"150","article-title":"Gene Ontology, Enrichment Analysis, and Pathway Analysis","author":"Zhou","year":"2017"},{"issue":"20","key":"10.1016\/j.bioorg.2026.110525_bb0435","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1080\/07391102.2023.2259476","article-title":"In-silico screening and molecular dynamics simulation of quinazolinone derivatives as PARP1 and STAT3 dual inhibitors: a novel DML approaches","volume":"42","author":"Dilipkumar","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0440","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40203-024-00261-w","article-title":"Discovery, lead identification and exploration of potential oxadiazole derivatives in targeting STAT3 as anti-cancer agents","volume":"12","author":"Panwar","year":"2024","journal-title":"In Silico Pharmacol."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110525_bb0445","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1021\/jm300207s","article-title":"Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein","volume":"55","author":"Debnath","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110525_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111922","article-title":"Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go?","volume":"187","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110525_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110525_bb0460","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110525_bb0465","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead-and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110525_bb0470","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1359-6446(99)01451-8","article-title":"Computational methods for the prediction of drug-likeness","volume":"5","author":"Clark","year":"2000","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110525_bb0475","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110525_bb0480","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/dmd.113.056176","article-title":"Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?","volume":"42","author":"Callaghan","year":"2014","journal-title":"Drug Metab. Dispos."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:17:33Z","timestamp":1791260253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":96,"alternative-id":["S0045206826010618"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110525","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thieno[2,3-d]pyrimidine scaffold optimization for synergistic c-Met\/STAT3 blockade: Synthesis, structure-activity relationships, in vitro potency, and apoptotic pathways in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110525"}}